Page last updated: 2024-11-13

coumermycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

coumermycin: RN given refers to coumermycin A1; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

coumermycin A1 : A hydroxycoumarin antibiotic that is obtained from Streptomyces rishiriensis and exhibits potent antibacterial and anticancer activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54675768
CHEMBL ID4555272
CHEBI ID3907
SCHEMBL ID194268
MeSH IDM0045751

Synonyms (43)

Synonym
nsc 107412
coumamycinum [inn-latin]
coumamycin (van)
1h-pyrrole-2-carboxylic acid, 5-methyl-, diester with n,n'-bis(7-((6-deoxy-5-c-methyl-4-o-methyl-alpha-l-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2h-1-benzopyran-3-yl)-3-methyl-1h-pyrrole-2,4-dicarboxamide
sugordomycin d-1a
pyrrole-2-carboxylic acid, 5-methyl-, diester with 3,3'-((3-methylpyrrole-2,4-diyl)bis(carbonylimino))bis(7-((5,5-di-c-methyl-4-o-methyl-alpha-l-lyxopyranosyl)oxy)-4-hydroxy-8-methylcoumarin)
cumamicina [inn-spanish]
brn 0470805
5-methylpyrrole-2-carboxylic acid, diester with 3,3'-((3-methylpyrrole-2,4-diyl)bis(carbonylimino))bis(4-hydroxy-8-methyl-7-((tetrahydro-3,4-dihydroxy-5-methoxy-6,6-dimethylpyran-2-yl)oxy)coumarin)
coumamycine [inn-french]
cumamycinum
coumermycin [usan]
notomycin a1
4434-05-3
coumamycin
nsc-107412
coumermycin a1
notomycin
sugordomycin d-la
coumermycin
C05073 ,
coumermycin (usan)
D02333 ,
pch9qz1iih ,
cumamicina
coumamycin [inn]
unii-pch9qz1iih
coumamycinum
coumamycine
SCHEMBL194268
1h-pyrrole-2,4-dicarboxamide, n2,n4-bis(7-((6-deoxy-5-c-methyl-4-o-methyl-3-o-((5-methyl-1h-pyrrol-2-yl)carbonyl)-.alpha.-l-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2h-1-benzopyran-3-yl)-3-methyl-
5-methylpyyrole-2-carboxylic acid, diester with 3,3'-((3-methylpyrrole-2,4-diyl)bis(carbonylimino))bis(4-hydroxy-8-methyl-7-((tetrahydro-3,4-dihydroxy-5-methoxy-6,6-dimethylpyran-2-yl)oxy)coumarin)
CHEBI:3907
(3-methyl-1h-pyrrole-2,4-diyl)bis[carbonylimino(4-hydroxy-8-methyl-2-oxo-2h-chromene-3,7-diyl)oxy(2r,3r,4s,5r)-3-hydroxy-5-methoxy-6,6-dimethyltetrahydro-2h-pyran-2,4-diyl] bis(5-methyl-1h-pyrrole-2-carboxylate)
BHW ,
CS-0129352
gtpl10879
[(3r,4s,5r,6r)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2r,3r,4s,5r)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1h-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1h-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen-
HY-N7452
CHEMBL4555272
DTXSID901023379
AKOS040755049
EX-A7846E

Research Excerpts

Overview

Coumermycin A1 is an aminocoumarin antibiotic produced by Streptomyces rishiriensis. It is an inhibitor of DNA gyrase, an enzyme that catalyzes supercoiling of DNA.

ExcerptReferenceRelevance
"Coumermycin A1 is a natural aminocoumarin that inhibits bacterial DNA gyrase, a member of the GHKL proteins superfamily. "( Structural Basis for DNA Gyrase Interaction with Coumermycin A1.
Chebaro, Y; Lamour, V; McEwen, AG; Potier, N; Vanden Broeck, A, 2019
)
2.21
"Coumermycin A1 is an aminocoumarin antibiotic produced by Streptomyces rishiriensis. "( Five gene products are required for assembly of the central pyrrole moiety of coumermycin A1.
Gust, B; Heide, L; Kulik, A; Novotna, J; Spizek, J, 2013
)
2.06
"Coumermycin A(1) is an aminocoumarin antibiotic produced by Streptomyces rishiriensis. "( Two pathways for pyrrole formation in coumermycin A(1) biosynthesis: the central pyrrole moiety is formed from L-threonine.
Burkard, N; Grond, S; Gust, B; Heide, L; Knuplesch, A; Siebenberg, S, 2011
)
2.08
"Coumermycin A(1) is a member of the aminocoumarin family of antibiotics. "( Assembly of dimeric variants of coumermycins by tandem action of the four biosynthetic enzymes CouL, CouM, CouP, and NovN.
Freel Meyers, CL; Heide, L; Kahne, D; Oberthür, M; Walsh, CT, 2004
)
2.05
"Coumermycin A1 is an inhibitor of DNA gyrase, an enzyme that catalyzes supercoiling of DNA and is required for bacterial DNA replication. "( Coumermycin A1 inhibits growth and induces relaxation of supercoiled plasmids in Borrelia burgdorferi, the Lyme disease agent.
Garon, CF; Samuels, DS, 1993
)
3.17
"Coumermycin A1 is an antibiotic isolated from Streptomyces hazeliensis var. "( Determination of coumermycin A1 in plasma by reversed-phase high-performance liquid chromatographic analysis.
Conzentino, P; de Silva, JA; Strojny, N, 1985
)
2.05

Effects

ExcerptReferenceRelevance
"Coumermycin has been shown to inhibit Staphylococcus aureus and Staphylococcus epidermidis strains that are susceptible and those that are resistant to methicillin at concentrations less than or equal to 0.05 micrograms/ml. "( Antibacterial activity of coumermycin alone and in combination with other antibiotics.
Chin, NX; Labthavikul, P; Neu, HC, 1984
)
2.01

Actions

ExcerptReferenceRelevance
"Coumermycin did not inhibit members of the family Enterobacteriaceae or Pseudomonas aeruginosa."( Antibacterial activity of coumermycin alone and in combination with other antibiotics.
Chin, NX; Labthavikul, P; Neu, HC, 1984
)
1.29

Treatment

ExcerptReferenceRelevance
"Coumermycin treatment reduced the proportion of supercoiled plasmid DNA in concert with a decrease in the rate of plasmid-coded synthesis of trp mRNA, implying a correlation between supercoiling of DNA and its suitability for transcription."( In vivo correlation between DNA supercoiling and transcription.
Imamoto, F; Kano, Y; Kuroki, K; Miyashita, T; Nagata, A; Nakamura, H, 1981
)
0.98

Compound-Compound Interactions

The bactericidal interactions in vitro of two antibiotics active at the cell wall (teicoplanin and vancomycin) or two inhibitors of DNA gyrase (coumermycin and ciprofloxacin) were assessed against five Staphylococcus aureus strains.

ExcerptReferenceRelevance
"The bactericidal interactions in vitro of two antibiotics active at the cell wall (teicoplanin and vancomycin) or two inhibitors of DNA gyrase (coumermycin and ciprofloxacin) combined with two inhibitors of protein synthesis (rifampicin and LM 427) were assessed against five Staphylococcus aureus strains."( Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus.
Joly, P; Van der Auwera, P, 1987
)
0.72
" Cl934 was also tested by the killing curve method, alone and in combination with coumermycin."( Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria.
Grenier, P; Klastersky, J; van der Auwera, P; Vandermies, A, 1987
)
0.72
" aureus but did not show synergy when combined with nafcillin, vancomycin, or rifampin."( Antibacterial activity of coumermycin alone and in combination with other antibiotics.
Chin, NX; Labthavikul, P; Neu, HC, 1984
)
0.57
"Ampligen, a known immunomodulator and interferon inducer, was used alone and in combination with other antiviral agents to treat ducks congenitally-infected with duck hepatitis B virus."( The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus.
Bowden, S; Dixon, R; Einck, L; Locarnini, S; Niu, J; Qiao, M; Wang, Y, 1993
)
0.52

Dosage Studied

The method was used to determine the plasma concentration--time profile of coumermycin A1 in the dog following a single intravenous administration of a 12 mg/kg dose of a solubilized dosage form of the bulk drug substance. The largest reductions of viable counts in the kidneys at each dosage as compared to the bacterial counts of untreated animals were achieved with coumer mycin.

ExcerptRelevanceReference
" The largest reductions of viable counts in the kidneys at each dosage as compared to the bacterial counts of untreated animals were achieved with coumermycin (3."( Efficacy of coumermycin, ofloxacin and vancomycin against methicillin-resistant Staphylococcus aureus in vitro and in experimental infections of mice.
Breyer, S; Georgopoulos, A; Hirschl, AM; Rotter, ML; Stanek, G, 1988
)
0.85
"The efficacy of a 5-day treatment with coumermycin A1 (hereafter referred to as coumermycin) (at three dosage regimens), with ciprofloxacin, or with coumermycin plus ciprofloxacin was tested in experimental aortic valve endocarditis induced in rats by a strain of methicillin-susceptible Staphylococcus aureus and was compared with the efficacy of a 5-day treatment with cloxacillin plus gentamicin."( Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.
Glauser, MP; Malinverni, R; Perronne, CM, 1987
)
0.78
" The method was used to determine the plasma concentration--time profile of coumermycin A1 in the dog following a single intravenous administration of a 12 mg/kg dose of a solubilized dosage form of the bulk drug substance."( Determination of coumermycin A1 in plasma by reversed-phase high-performance liquid chromatographic analysis.
Conzentino, P; de Silva, JA; Strojny, N, 1985
)
0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
DNA synthesis inhibitorAny substance that inhibits the synthesis of DNA.
topoisomerase IV inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase IV, which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
Hsp90 inhibitorAn EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor that blocks the action of heat shock protein 90.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
coumarins
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
pyrrolesAn azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton.
heteroarenecarboxylate ester
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1513555Antiproliferative activity against human SKBR3 cells2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design.
AID1513556Antiproliferative activity against human MCF7 cells2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (216)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990102 (47.22)18.7374
1990's43 (19.91)18.2507
2000's47 (21.76)29.6817
2010's23 (10.65)24.3611
2020's1 (0.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.76 (24.57)
Research Supply Index5.38 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index34.82 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (1.84%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other213 (98.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]